SAN JOSE, Calif., March 16, 2018 /PRNewswire/ -- ITUS
Corporation (NASDAQ: ITUS), today announced that it will present
the latest data from its ongoing early cancer detection study at
the annual meeting of the American Association of Immunologists
(AAI) in Austin, Texas. The
meeting will be held May 4-8, 2018
and will be attended by physicians and scientists dedicated to
understanding and advancing the field of immunology.
ITUS's proprietary Cchek™ technology combines immunophenotyping,
or analysis of white blood cells, with artificial intelligence (AI)
to detect the presence of solid tumor from a blood sample.
ITUS utilizes flow cytometry for immunophenotyping by monitoring
leukocytes (white blood cells) focusing on a recently discovered
class of cells known as Myeloid Derived Suppressor Cells
(MDSCs). These cells, as well as other myeloid and lymphoid
cells, comprise the human immune system, and ITUS's Cchek™ monitors
perturbations in the immune system to identify tumors. An
Artificial Intelligence application known as a Neural Network is
utilized to perform the analysis.
"We are pleased that our presentation was accepted for this
conference, as our focus is on monitoring the immune system to
catch cancer early, and this audience is focused on
immunology. Blood bathes all organs of the body, and within
it are the signals that indicate disease. For early cancer
detection it has been hard to identify those signals because they
are so rare. With our flow cytometry protocols coupled with
Artificial Intelligence, we have demonstrated an excellent ability
to identify the signals that distinguish tumor-bearing patients
from healthy individuals," stated Dr. Amit
Kumar, President and CEO of ITUS Corporation. "After
this presentation, we will have presented our technology at four
scientific conferences in four consecutive months. We will
continue to expose our technology to the scientific community, the
biotech industry, and to corresponding investors," added Dr.
Kumar.
American Association of Immunologists (AAI)
The
American Association of Immunologists (AAI) (www.aai.org) is a
scientific society headquartered in Rockville, MD and is an association of
professionally trained scientists from all over the world dedicated
to advancing the knowledge of immunology and its related
disciplines, fostering the interchange of ideas and information
among investigators, and addressing the potential integration of
immunologic principles into clinical practice. The
association serves its members by providing a center for the
dissemination of information relevant to the field and its
practices such as educational and professional opportunities,
scientific meetings, membership-derived issues and opinions, and
important funding and policy issues. AAI owns and
publishes The Journal of Immunology, the largest and
most highly cited journal in the field, as well
as ImmunoHorizons, an open access, peer-reviewed
journal dedicated to the science of immunology.
ITUS Corporation
ITUS, a cancer-focused biotechnology
company, is harnessing the body's immune system in the fight
against cancer. Its wholly owned subsidiary, Anixa
Diagnostics Corporation, is developing the CchekTM
platform, a series of non-invasive blood tests for the early
detection of solid tumor-based cancers, which is based on the
body's immunological response to the presence of a
malignancy. Its majority owned subsidiary, Certainty
Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs
which genetically engineer a patient's own immune cells to fight
cancer. ITUS also continually examines emerging technologies
in complementary or related fields for further development and
commercialization. Additional information is available at
www.ITUScorp.com.
Forward-Looking Statements: Statements that are
not historical fact may be considered forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical facts, but rather reflect ITUS Corporation's current
expectations concerning future events and results. We generally use
the words "believes," "expects," "intends," "plans," "anticipates,"
"likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We
undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You are
cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
ITUS Corporation: FOCUSED ON INNOVATION™
View original content with
multimedia:http://www.prnewswire.com/news-releases/itus-to-present-data-from-early-cancer-detection-study-utilizing-artificial-intelligence-at-the-american-association-of-immunologists-aai-meeting-300615051.html
SOURCE ITUS Corporation